Unibest

Pharmaceutical intermediates

Ceritinib Intermediates

5 pharmaceutical intermediates for Ceritinib. Indication: Non-small cell lung cancer.

Submit a ProjectAll intermediates

About Ceritinib

Originator
Novartis Pharmaceuticals Corp
Indication
Non-small cell lung cancer
Approved Date
04/29/2014
DS/DP
04/25/2026

Available intermediates

5 intermediates currently listed for Ceritinib. Request specifications, documentation or a quotation for any item below.

Ceritinib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
2,5-Dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidin -4-amine761440-16-8//
2-Isopropylthioaniline hydrochloride861343-73-9//
5-Methyl-2-(1-methylethoxy)-4-(4-piperidinyl)benzenamine hydrochloride (1:2)1380575-45-0//
1-Chloro-5-isopropoxy-2-methyl-4-nitrobenzene1032903-50-6//
2-Isopropoxy-5-methyl-4-(piperidin-4-yl)aniline dihydrochloride hydrate1802250-63-0//

Other programs under C

Cabozantinib S-malateCalcipotriolCalcitriolCamlipixantCanagliflozinCangrelor TetrasodiumCapivasertib Capmatinib Hydrochloride

Building toward Ceritinib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

Submit a Project Talk to the team

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here

Contact Us →